These results are in agreement with those from previous studies [11, 12, 14], including one by our group, which showed that the relative abundance of the EGFR mutation in tumor tissues was associated with the benefits from EGFR-TKIs treatment [23]. This evidence concerns the gene EGFR and neoplasm.